NYSE:ABBVBiotechs
AbbVie Seeks Rinvoq Vitiligo Approval And Extends Immunology Growth Story
AbbVie has submitted regulatory applications to the FDA and EMA for Rinvoq as a potential systemic treatment for non segmental vitiligo.
The filings target a condition where there are currently no approved systemic therapies, highlighting a major unmet medical need.
The move could broaden the use of one of AbbVie's key immunology assets beyond its existing indications.
For investors following AbbVie, NYSE:ABBV, this update comes with the stock recently closing at $223.43. The company has...